Targeted genomic analysis of Müllerian adenosarcoma

Journal of Pathology

Volumn 235, Issue 1, 2015, Pages 37-49

  Howitt, Brooke E ^a   Sholl, Lynette M ^a   Dal Cin, P ^a   Jia, Yonghui ^a   Yuan, Liping ^a   MacConaill, Laura ^a   Lindeman, Neal ^a   Kuo, Frank ^a   Garcia, Elizabeth ^a   Nucci, Marisa R ^a   Quade, Bradley J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenosarcoma; HMGA2; MDM2; MYBL1; M llerian; Sarcomagenesis

Indexed keywords

CYCLIN DEPENDENT KINASE 4; HIGH MOBILITY GROUP A2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53;

ADENOSARCOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; COPY NUMBER VARIATION; EXON; FEMALE; FEMALE GENITAL TRACT CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; MISSENSE MUTATION; MULLERIAN ADENOSARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; TUMOR SUPPRESSOR GENE; AGED; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADENOSARCOMA; ADULT; AGED; AGED, 80 AND OVER; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84916227470     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4442     Document Type: Article

References (59)

1. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of Mullerian mixed tumor. Cancer 1974; 34: 1138-1149.
2. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 1990; 21: 363-381.
3. Eichhorn JH, Young RH, Clement PB, et al. Mesodermal (Müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 2002; 26: 1243-1258.
4. Kurman R, Carcangiu ML, Young RH (Eds). World Health Organization Classification of Tumours of Female Reproductive Organs. IARC Press: Lyon, 2014.
5. McCluggage WG. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol 2010; 17: 122-129.
6. Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer 1981; 48: 354-366.
7. Kaku T, Silverberg SG, Major FJ, et al. Adenosarcoma of the uterus: a gynecologic oncology group clinicopathologic study of 31 cases. Int J Gynecol Pathol 1992; 11: 75-88.
8. Amant F, Schurmans K, Steenkiste E, et al. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol 2004; 93: 680-685.
9. Amant F, Steenkiste E, Schurmans K, et al. Immunohistochemical expression of CD10 antigen in uterine adenosarcoma. Int J Gynecol Cancer 2004; 14: 1118-1121.
10. Auerbach HE, LiVolsi VA, Merino MJ. Malignant mixed Mullerian tumors of the uterus. An immunohistochemical study. Int J Gynecol Pathol 1988; 7: 123-130.
11. Gallardo A, Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol 2009; 33: 278-288.
12. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol 2008; 32: 1013-1021.
13. Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 2011; 30: 236-243.
14. Mikami Y, Hata S, Kiyokawa T, et al. Expression of CD10 in malignant Müllerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod Pathol 2002; 15: 923-930.
15. Blom R, Guerrieri C. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases. Int J Gynecol Cancer 1999; 9: 37-43.
16. Swisher EM, Gown AM, Skelly M, et al. The expression of epidermal growth factor receptor, Her-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996; 60: 81-88.
17. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213-219.
18. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
19. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet 2011; 43: 491-498.
20. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high-confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinform 2013; 43: 11.10.1-11.10.33.
21. Garcia EP, Kuo F, Jia Y, Zepf D, et al. Development and clinical validation of a targeted next-generation sequencing platform for the detection of somatic mutations, indels, rearrangements, and copy-number alterations in human tumors. J Mol Diagn 2013; 15: 872.
22. Spencer DH, Sehn JK, Abel HJ, et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn 2013; 15: 623-633.
23. Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014; 146: 453-460.e455.
24. de Wilde RF, Heaphy CM, Maitra A, et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of Men-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol 2012; 25: 1033-1039.
25. Krivak TC, Seidman JD, McBroom JW, et al. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 2001; 83: 89-94.
26. Kobayashi H, Uekuri C, Akasaka J, et al. The biology of uterine sarcomas: a review and update. Mol Clin Oncol 2013; 1: 599-609.
27. Gollard R, Kosty M, Bordin G, et al. Two unusual presentations of Müllerian adenosarcoma: case reports, literature review, and treatment considerations. Gynecol Oncol 1995; 59: 412-422.
28. Bernard B, Clarke BA, Malowany JI, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol 2013; 131: 634-639.
29. Fox H, Harilal KR, Youell A. Müllerian adenosarcoma of the uterine body: a report of nine cases. Histopathology 1979; 3: 167-180.
30. Manoharan M, Azmi MA, Soosay G, et al. Mullerian adenosarcoma of uterine cervix: report of three cases and review of literature. Gynecol Oncol 2007; 105: 256-260.
31. Van Mieghem T, Abeler VM, Moerman P, et al. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecol Oncol 2005; 99: 493-496.
32. Taylor NP, Zighelboim I, Huettner PC, et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006; 19: 1333-1338.
33. Anderson SE, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer 2006; 16: 849-853.
34. Liu FS, Kohler MF, Marks JR, et al. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994; 83: 118-124.
35. Ito M, Barys L, O'Reilly T, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011; 17: 416-426.
36. Sprogoe-Jakobsen S, Holund B. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus). APMIS 1996; 104: 705-708.
37. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3: 709-722.
38. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genet 2014; 46: 444-450.
39. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
40. Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013; 110: 8188-8193.
41. Chen Z, Hong B, Drozd-Borysiuk E, et al. Molecular cytogenetic characterization of a case of Müllerian adenosarcoma. Cancer Genet Cytogenet 2004; 148: 129-132.
42. Dei Tos AP, Doglioni C, Piccinin S, et al. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol 1997; 181: 8-13.
43. Maekawa Y, Tsukumo S, Chiba S, et al. Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity 2003; 19: 549-559.
44. Tallini G, Vanni R, Manfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 2000; 80: 359-369.
45. Dal Cin P, Timmerman D, Van den Berghe I, et al. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 1998; 58: 2278-2281.
46. Dal Cin P, Van Den Berghe H, Brosens I. Involvement of 6p in an endometrial polyp. Cancer Genet Cytogenet 1991; 51: 279-280.
47. Dal Cin P, Vanni R, Marras S, et al. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res 1995; 55: 1565-1568.
48. Vanni R, Dal Cin P, Marras S, et al. Endometrial polyp: another benign tumor characterized by 12q13-q15 changes. Cancer Genet Cytogenet 1993; 68: 32-33.
49. Bol S, Wanschura S, Thode B, et al. An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Cancer Genet Cytogenet 1996; 90: 88-90.
50. Walter TA, Fan SX, Medchill MT, et al. inv(12)(p11.2q13) in an endometrial polyp. Cancer Genet Cytogenet 1989; 41: 99-103.
51. Speleman F, Dal Cin P, Van Roy N, et al. Is t(6;20)(p21;q13) a characteristic chromosome change in endometrial polyps? Genes Chromosomes Cancer 1991; 3: 318-319.
52. Medeiros F, Erickson-Johnson MR, Keeney GL, et al. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. Genes Chromosomes Cancer 2007; 46: 981-990.
53. Nucci MR, Weremowicz S, Neskey DM, et al. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes Cancer 2001; 32: 172-176.
54. Medeiros F, Araujo AR, Erickson-Johnson MR, et al. HMGA1 and HMGA2 rearrangements in mass-forming endometriosis. Genes Chromosomes Cancer. 2010; 49: 630-634.
55. Dal Cin P, Kools P, De Jonge I, et al. Rearrangement of 12q14-15 in pulmonary chondroid hamartoma. Genes Chromosomes Cancer 1993; 8: 131-133.
56. Dal Cin P, Turc-Carel C, Sandberg AA. Consistent involvement of band 12q14 in two different translocations in three lipomas from the same patient. Cancer Genet Cytogenet 1988; 31: 237-240.
57. Dal Cin P, Wanschura S, Kazmierczak B, et al. Amplification and expression of the HMGIC gene in a benign endometrial polyp. Genes Chromosomes Cancer 1998; 22:95-99.
58. Tesfaye A, Di Cello F, Hillion J, et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007; 67: 3998-4004.
59. Boo LM, Lin HH, Chung V, et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 2005; 65: 6622-6630.